Novo Nordisk A/S’ NVO Canada system on Thursday revealed that Health Canada has actually accepted for evaluation, under the Concern Evaluation policy, its additional brand-new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly treatment for individuals dealing with MASH (metabolic dysfunction-associated steatohepatitis).
” Semaglutide 2.4 mg represents a healing development for clients dealing with MASH, attending to an important unmet medical requirement,” states Vince Lamanna, President of Novo Nordisk Canada Inc. “Health Canada’s approval of the Semaglutide 2.4 mg submission for evaluation brings us one action more detailed to offering the very first treatment alternative for qualified individuals dealing with MASH.”
Likewise Check Out: Eli Lilly Positioned To Control Weight Problems Market With Oral Alternative, Expert Starts With Self-confidence
In November 2024, Health Canada authorized Wegovy (semaglutide injection) to minimize the threat of non-fatal myocardial infarction (MI) in grownups with recognized heart disease and a BMI equivalent to or higher than 27 kg/m2.
It was the very first Health Canada-approved treatment to support both persistent weight management and to minimize the threat of non-fatal MI.
MASH is a persistent, progressive metabolic illness impacting the liver.
Amongst individuals who are obese or have weight problems, about one in 3 likewise have MASH.
Excess fat can develop in the liver, which, with time, can cause swelling and extreme scarring of the liver.
By 2030, the occurrence of MASH in the Canadian basic population is approximated to increase from 5.2% to 6.5%.
In Canada, the variety of deaths is anticipated to double in individuals dealing with MASH by 2030.
On Thursday, Novo Nordisk revealed that CVS Health Inc’s CVS CVS Caremark, a Drug Store Advantage Supervisor (PBM), chose that Wegovy ( semaglutide) injection 2.4 mg will quickly be the favored GLP-1 medication on its biggest industrial design template formularies.
This modification will work on July 1, 2025.
In February, the FDA validated that all dosages of Wegovy were offered. In March, Novo Nordisk released NovoCare Drug store to supply direct-to-patient, hassle-free home deliveries of all Wegovy dosage strengths at a minimized expense of $ 499 each month for self-paying clients.
More just recently, the Wegovy cost savings deal was upgraded, enabling qualified self-paying clients to get the $ 499-per-month cost at their regional drug store.
On Tuesday, Novo Nordisk and Hims & & Hers Health, Inc HIMS revealed a long-lasting cooperation.
The business stated that people might be recommended Wegovy at a single, unified cost beginning at $599 each month. The offering is offered today on the Hims & & Hers platform.
This brand-new offering develops on Hims & & Hers’ existing suite of weight-loss options and offers self-pay clients with access to all dosage strengths of Wegovy in a premium pen.
Rate Action: NVO stock is up 5.5% at $69.21 at last check Friday.
Read Next:
Image: Shutterstock